Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
– Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter –
– As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue –
WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ('Verrica' or the 'Company') (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Company experienced strong demand-led growth for YCANTH® in the first quarter of 2025, with the number of dispensed applicator units increasing to 10,102 in the first quarter. This first quarter growth represents a sequential increase of 16.7% over the fourth quarter of 2024 (8,654 dispensed applicator units).
'We believe the strong performance we experienced for YCANTH in first quarter of 2025 reflects the positive impact from our recent commercial restructuring,' said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. 'Importantly, our YCANTH distribution inventory has normalized. The sequential growth in the first quarter represents increasing demand for YCANTH by prescribers, which we believe will drive revenue.' Dr. Rieger emphasized, ' With strong market access now in place, normalized channel inventory levels, and a more focused commercial team that continues to build solid relationships within the dermatology and pediatric communities, I believe we are now positioned for sustainable revenue growth in 2025 and beyond as we seek to establish YCANTH as the standard of care for the treatment of molluscum contagiosum.'
Company to Participate in Fireside Chat at 24th Annual Needham Virtual Healthcare Conference
As previously announced, Dr. Rieger will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.
Event details:
Date: Tuesday, April 8, 2025
Time: 1:30 pm ET
Location: Virtual
Participants may access a live webcast of the event by clicking the link here.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
About YCANTH® (VP-102)YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH® is the first and only commercially available product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH® was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH® was a safe and effective therapeutic for the treatment of molluscum. Approximately 225 million lives are eligible to receive YCANTH® covered by insurance. YCANTH® is available to all patients with and without insurance coverage for $25 per treatment, and further financial assistance is available for patients in need. Please visit YCANTHPro.com for additional information.
About Verrica Pharmaceuticals Inc.Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
About Dispensed Applicator UnitsDispensed applicator units represent applicators (a) shipped to healthcare professionals from Verrica's contracted pharmacy partners for fulfillment, (b) sold by Verrica's distribution partners to independent and regional pharmacies , and (c) sold to physician offices, hospitals and other clinics on a buy and bill basis.
Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 'believe,' 'expect,' 'may,' 'plan,' 'potential,' 'will,' and similar expressions, and are based on Verrica's current beliefs and expectations. These forward-looking statements include statements about Verrica's ability to sustain revenue growth, the commercialization of YCANTH and the clinical development and benefits of Verrica's product candidates, including YCANTH (VP-102) and VP-315. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the proposed public offering and other risks and uncertainties that are described in Verrica's Annual Report on Form 10-K for the year ended December 31, 2024 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby Interim Chief Financial Officer jkirby@verrica.com
Kevin GardnerLifeSci Advisorskgardner@lifesciadvisors.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Why Broadcom Inc. (AVGO) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where Broadcom Inc. (NASDAQ:AVGO) stands against other Friday's worst-performing stocks. Broadcom dropped its share prices for a second day on Friday, shedding 5 percent to finish at $246.93 apiece as investors appeared to have already priced in its impressive earnings performance for the second quarter of fiscal year 2025. In a statement, Broadcom Inc. (NASDAQ:AVGO) said it netted $4.965 billion during the period, higher by 134 percent than the $2.121 billion in the same period last year. Revenues also increased by 20 percent to $15 billion from $12.487 billion. A technician working at a magnified microscope, developing a new integrated circuit. 'Broadcom achieved record second quarter revenue on continued momentum in AI semiconductor solutions and VMware. [Second quarter] AI revenue grew 46 percent year-over-year to over $4.4 billion, driven by robust demand for AI networking,' Broadcom Inc. (NASDAQ:AVGO) President and CEO Hock Tan. 'We expect growth in AI semiconductor revenue to accelerate to $5.1 billion in Q3, delivering ten consecutive quarters of growth, as our hyperscale partners continue to invest,' he added. Broadcom Inc. (NASDAQ:AVGO) also declared a cash dividend of $0.59 per share to stockholders as of June 20 record, payable on June 30. Overall, AVGO ranks 6th on our list of Friday's worst-performing stocks. While we acknowledge the potential of AVGO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
32 minutes ago
- Yahoo
Veteran fund manager resets stock market forecast amid Musk, Trump fallout
Veteran fund manager resets stock market forecast amid Musk, Trump fallout originally appeared on TheStreet. Put two mercurial personalities in the room, add competing goals and a hefty dose of media pressure, and what do you get? Let's just say that the high-profile friend-to-foe saga isn't overly surprising. Elon Musk and Donald Trump are polarizing figures with a penchant for dropping verbal bombshells, and that was particularly evident this week as the two sparred over the Big Beautiful bill, electric vehicle credits, and debt. The rift may shock some, however, given how closely Musk and Trump worked together over the past year. 💵💰Don't miss the move: Subscribe to TheStreet's free daily newsletter 💰💵 Musk spent hundreds of millions helping elect Donald Trump as president, and Trump rewarded Musk with a high-profile role in his administration as the head of the Department of Government Efficiency, or DOGE. Trump even went so far as to host a Tesla showroom on the White House lawn to support Musk after Musk's political activism caused a drop in Tesla's sales. One person who wasn't the least bit surprised by the high-profile dust-up was veteran hedge fund manager Doug Kass. Back in December, Kass picked the break-up as one of his top 15 surprises for 2025. It was far from the only correct forecast for Kass. He also predicted a stock market reckoning could cause the S&P 500 to fall 15%, and in April, he accurately forecast that stocks would find their footing after the brutal sell-off. Kass recently revisited his take on Musk and Trump, and how stocks may react to their fallout. His S&P 500 outlook may disappoint many, while his take on Trump and Musk might surprise most. After back-to-back 20% gains in the S&P 500 in 2023 and 2024, including an impressive 24% return last year, investors may have complacently expected more good times in 2025. Then reality set in. The stock market has whipsawed amid a series of shocks, many delivered by President Trump and Elon Musk, via his high-profile and much-debated cost-cutting at came into 2025 arguably priced to perfection. Optimism for a friendly Federal Reserve shift in monetary policy to dovish interest rate cuts and a flood of artificial intelligence spending fueled big returns last year, pushing the S&P 500's price-to-earnings ratio north of 22. Historically, returns following high P/E ratios have been largely lackluster. That point wasn't lost on Kass, who correctly said in December that the S&P 500 could drop 15% in 2025. "Surprise #9: In 2025, the S&P Index falls by about 15%. The technology-laden Nasdaq drops by over 20%," wrote Kass. Kass beat the bearish drum continuously through February, when the S&P 500 reversed after hitting all-time highs. From mid-February through early April, bombshells in the form of shockingly high tariff announcements from President Trump and job losses stemming from Musk's DOGE efforts caused the benchmark index to plummet. At its worst, the S&P 500 fell 19%, while the tech-heavy Nasdaq fell about 24%. The sharp drop was painful, and many hit the sell button, worried that an endless stream of uncertainty would cause even greater losses. Kass, however, correctly reversed course, making bargain-basement buys on the indexes and tech leaders, including Amazon, near the lows. Since then, Trump's pause on tariffs and potential for trade deals that ease the tariffs' bite have helped fuel a dramatic recovery, lifting the S&P 500 by 20%. More Economic Analysis: Hedge-fund manager sees U.S. becoming Greece A critical industry is slamming the economy Reports may show whether the economy is toughing out the tariffs The result has been a nausea-inspiring roller coaster ride for buy-and-hold investors. That's been particularly true for Tesla () shareholders. The EV company rallied after Trump's election amid hope that Musk's White House connections would pave the way to sales growth. Instead, Musk's DOGE efforts, and arguably controversial political comments, caused a mass exodus of left-leaning Tesla buyers. Sales cratered in key markets, including Europe and California, the largest U.S. auto market. In Europe, Tesla sales dropped 49% year-over-year in April to 7,261 vehicles, according to the European Automobile Manufacturers' Association. In California, Tesla registrations fell 21.5% year-over-year in the first quarter, while non-Tesla electric vehicle (EV) registrations grew 14%. Tesla's stock price got hammered as a result, falling 54% from mid-December highs to early April lows. It's since recovered alongside the broad market, jumping 35%, largely on news Elon Musk would step away from DOGE. Doug Kass has seen a thing or two. His career stretches back into the 1970s at money manager Putnam, including a stint as research director for billionaire Leon Cooperman's Omega Advisors. His deep experience navigating markets professionally means he had a front-row seat to his share of political, economic, and stock market surprises. He witnessed Richard Nixon's Watergate implosion, the inflation-riddled 70s, the Savings & Loan crisis, the Internet boom and bust, hanging chads, the housing-bubble-driven Great Financial Recession, Trump presidency version 1.0, Covid, and the recent inflation shock and December, he tests that experience with his "surprises" list for the coming year. This year, in addition to predicting the S&P 500 sell-off, he forecast the unfriendly end of the Trump-Musk relationship. "Surprise #2: The 'other' romance, between Trump/Musk, doesn't make it past spring 2025," wrote Kass. "National protests and demonstrations emerge and demands from a wide array of members of both the Republican and Democratic parties (including conservatives and liberals) call for 'ousting' Elon Musk, an unelected official, from playing such a dominant role in the U.S. government." Kass's Musk prediction is a longer read, but the gist is simple: Musk and Trump will suffer a fallout, which may have consequences for investors. He revisited his outlook, offering a new take on the Trump-Musk situation. "Right in front of us, it is obvious that political positions of influence can easily be bought-sold by both parties (and that certainly includes the presidency)," wrote Kass. "I am not even sure where the performance ends and reality begins. In the end (probably sooner than later) — just like the president's opening salvos of ridiculously high tariff proposals — the two actors will likely have a detente (and kiss and make up) because the downside is certain for both of them, as no one will win. When that make-up happens, no one knows. It could happen today, next week or next month, but the parties' 'interests' are now so enmeshed that Musk and Trump recognize where their bread is buttered." A potential "easing" of tensions would be welcome, given that a long-term tit-for-tat would fuel market volatility. Still, Kass's view of what happens to the stock market next isn't encouraging. "Never in my investing career has there been so many possible social, political, geopolitical, economic, interest rates and fiscal policy outcomes (many of which are adverse). That is why I don't understand the uber confidence expressed by the Perma Bull cabal (led by Fundstrat's Tom Lee) and manifested in a near-vertical move higher for equities over the last two months," continued Kass. "With a forward PE of 22x, equities remain overvalued and, after covering my Index shorts yesterday, I plan to reshort any rally." If Kass is correct that instability will force stocks lower, how low could it go, and when might things improve? "I see seven lean months ahead for our markets. We estimate downside risk to be roughly 3x the upside reward," concludes fund manager resets stock market forecast amid Musk, Trump fallout first appeared on TheStreet on Jun 7, 2025 This story was originally reported by TheStreet on Jun 7, 2025, where it first appeared. Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
Why Braze, Inc. (BRZE) Crashed On Friday
We recently published a list of . In this article, we are going to take a look at where Braze, Inc. (NASDAQ:BRZE) stands against other Friday's worst-performing stocks. Braze Inc. dropped its share prices by 17.65 percent on Friday to finish at $29.73 apiece as investors soured on its dismal earnings performance in the first quarter of fiscal year 2026. In a statement, Braze, Inc. (NASDAQ:BRZE) said attributable net loss was unchanged at $35 million, despite revenues increasing by 20 percent to $162 million from $135 million, driven primarily by new customers, upsells, and renewals. A web developer hunched over their laptop coding a customer engagement platform. For the second quarter of the year, Braze, Inc. (NASDAQ:BRZE) is targeting to hit $171 million to $172 million in revenues, with a net income ranging from $2.5 million to $3.5 million. The full-year period alone is expected to rake in between $702 million and $706 million in revenues, and a net income of $17 million to $21 million. The company also welcomed Ed McDonnell as its new chief revenue officer. 'McDonnell has a strong track record of delivering results at high-growth public SaaS businesses, and we believe his extensive background in Software and Customer Engagement will further solidify Braze as the leading customer engagement platform and accelerate growth in the coming years,' said Braze, Inc. (NASDAQ:BRZE) CEO Bill Magnuson. Overall, BRZE ranks 3rd on our list of Friday's worst-performing stocks. While we acknowledge the potential of BRZE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
